Flt3 Ligand Dendritic Cell Mobilization for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for solid tumors, face challenges in effectively mobilizing dendritic cells and enhancing immune responses, leading to limited overall survival and progression-free survival in cancer patients, especially those resistant to immunoregulatory agents or immune checkpoint inhibitors.
Innovation Solution
Administering a dendritic cell mobilizing agent, such as Flt3 ligand, in combination with radiation therapy and/or immunoregulatory agents, including immune checkpoint inhibitors, to enhance dendritic cell mobilization and activation, thereby improving immune response and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunoregulatory agents or immune checkpoint inhibitors are administered alone, then immune response is stimulated, but treatment efficacy is limited in resistant cancer patients
Solution Approach 1:
The patent combines dendritic cell mobilizing agents (such as Flt3 ligand) with immunoregulatory agents and/or radiation therapy to create a multi-component treatment regimen. This combination approach addresses resistance by engaging multiple immune pathways simultaneously - the dendritic cell mobilizing agent increases DC numbers and activity, while the immunoregulatory agent blocks inhibitory checkpoints, creating synergistic anti-tumor immunity that overcomes single-agent resistance
Solution Approach 2:
The treatment protocol uses a composite therapeutic approach combining different mechanism-based agents: dendritic cell mobilizing agents (Flt3 ligand), immunoregulatory agents (checkpoint inhibitors like anti-PD-1, anti-CTLA-4), and radiation therapy. This composite regimen targets multiple aspects of the immune response and tumor microenvironment, providing adaptability against diverse resistance mechanisms
2Quantity of substance
If dendritic cell mobilizing agents are administered to increase dendritic cell numbers, then immune response is enhanced, but treatment complexity increases
Solution Approach 1:
The dendritic cell mobilizing agent (Flt3 ligand) is administered to preliminarily increase dendritic cell numbers and activation status before or during the course of immunoregulatory therapy and radiation. This preliminary expansion of the dendritic cell pool ensures sufficient antigen-presenting cells are available to respond to subsequent immune stimulation, simplifying the overall treatment by pre-conditioning the immune system
Solution Approach 2:
Flt3 ligand serves multiple functions: it mobilizes dendritic cells from bone marrow, promotes dendritic cell differentiation, enhances dendritic cell maturation, and stimulates dendritic cell antigen-presenting capacity. This multi-functionality reduces treatment complexity by using a single agent to achieve multiple immune-enhancing effects that would otherwise require multiple separate interventions
3Duration of action of stationary object
If combination therapy is used to overcome resistance, then overall survival improves, but treatment cost and complexity increase
Solution Approach 1:
The treatment protocol employs periodic administration schedules where dendritic cell mobilizing agents, immunoregulatory agents, and radiation therapy are given in defined cycles and sequences. This periodic structuring manages complexity by establishing clear treatment phases and intervals, making the combination regimen more manageable while maintaining the synergistic benefits of multiple agents
Solution Approach 2:
The combination therapy is segmented into distinct treatment components with specific roles: dendritic cell mobilizing agents for DC expansion, immunoregulatory agents for checkpoint blockade, and radiation for local tumor control. This segmentation allows each component to be optimized independently while maintaining overall regimen simplicity through clear division of therapeutic functions
Data Source
AI summary
Methods of treating cancer comprising administering to patients a dendritic cell mobilizing agent (e.g., Flt3 ligand) in combination with radiation and/or immunoregulatory agents (e.g., checkpoint inhibitors), are disclosed.